Dineromail apixaban

Apixaban is a direct oral anticoagulant (DOAC) used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib). Here's a summary of the key information about apixaban:

Brand Name: Eliquis

Indications:

• Prevention of stroke and systemic embolism in patients with non-valvular AFib
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Mechanism of Action:

• Apixaban is a direct thrombin inhibitor that works by inhibiting the activity of thrombin, a protein involved in the formation of blood clots
• It does not require anticoagulant therapy monitoring, such as prothrombin time (PT) or international normalized ratio (INR) testing

Dosage:

• For AFib: 5 mg twice daily
• For DVT and PE: 10 mg twice daily for the first 7-10 days, then 5 mg twice daily

Contraindications:

• Hypersensitivity to apixaban
• Active pathological bleeding
• Mechanical prosthetic heart valves
• Severe renal impairment (CrCl < 15 mL/min)

Adverse Reactions:

• Common: bleeding, bruising, dyspepsia, nausea, vomiting
• Serious: bleeding, including intracranial hemorrhage, gastrointestinal bleeding, and hematuria

Interactions:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase apixaban levels
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease apixaban levels
• P-glycoprotein inhibitors (e.g., verapamil, amiodarone) may increase apixaban levels

Pregnancy and Lactation:

• Apixaban is not recommended during pregnancy or breastfeeding due to the potential risk of bleeding and the unknown effects on the fetus or infant

Monitoring:

• Regular monitoring of bleeding risk and platelet count is recommended
• Patients should be advised to report any signs or symptoms of bleeding to their healthcare provider

Dosing Adjustments:

• For patients with severe renal impairment (CrCl < 15 mL/min), the recommended dose is 2.5 mg twice daily
• For patients with mild to moderate hepatic impairment, the recommended dose is 5 mg twice daily

Special Populations:

• Elderly patients: Apixaban is not recommended for patients with severe renal impairment or those who are 80 years or older
• Pediatric patients: Apixaban is not recommended for patients under 18 years of age

Important Safety Information:

• Apixaban may increase the risk of bleeding, including intracranial hemorrhage, gastrointestinal bleeding, and hematuria
• Patients should be advised to report any signs or symptoms of bleeding to their healthcare provider
• Apixaban is not recommended for patients with mechanical prosthetic heart valves or those who are at high risk of bleeding

It's essential to consult the product labeling and consult with a healthcare provider for specific guidance on the use of apixaban in individual patients.